Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Lynette Chee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real‐world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)‐resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib‐pretreated cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
- Bendigo Cancer Centre, Bendigo Hospital, Bendigo, Victoria, Australia.
- Department of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia.
- Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
- Department of Haematology, Box Hill Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Lynette Chee, Andrew Grigg, Jeff Szer
Zitieren
APA
Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., Ratnasingam, S., Raj, S., Lukito, P., Yeung, D., Hughes, T., & Shanmuganathan, N. (2024). Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.16446
Vancouver
Chee L, Lee N, Grigg A, Chen M, Schwarer A, Szer J, et al. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia. Internal Medicine Journal. 2024. doi:10.1111/imj.16446
BibTeX
@article{Chee2024,
author = {Chee, Lynette and Lee, Nora and Grigg, Andrew and Chen, Melissa and Schwarer, Anthony and Szer, Jeff and Ratnasingam, Sumita and Raj, Sonia and Lukito, Pohan and Yeung, David and Hughes, Timothy and Shanmuganathan, Naranie},
title = {Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16446}
}
EUVIMED